Related Experiment Video
Updated: Sep 8, 2025
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Practical Considerations for Implementation of 177Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
Diane K Soulek1, Nic J Mastascusa1, Molly E Martin1
1University of Iowa Hospitals and Clinics, United States.
Abstract:
The 2018 FDA approval of 177Lu-DOTATATE for the treatment of somatostatin receptor-positive (SSTR) neuroendocrine tumors (NETs) represents a paradigm shifting approach to cancer treatments around the globe. Gastroenteropancreatic (GEP) NETs overexpress the somatostatin subtype receptor 2, which is now exploited for receptor-based imaging and therapy, thus generating significant progress in the diagnosis and treatment of this orphan disease. The recent FDA approval of receptor-based PET radiopharmaceuticals and a new peptide receptor radiopharmaceutical therapy (PRRT), 177Lu-DOTATATE, has dramatically impacted NET patient management. The focus of this paper is to review clinical considerations associated with implementing a 177Lu-DOTATATE program. We review receptor-based NET radiopharmaceuticals, 177Lu-DOTATATE patient selection criteria, administration methods, clinical, regulatory, and radiation safety considerations, technical factors, tissue dosimetry, and reimbursement guidelines.
Insights
The FDA-approved 177Lu-DOTATATE offers a new treatment for neuroendocrine tumors (NETs). This review covers key aspects of implementing this peptide receptor radiopharmaceutical therapy (PRRT) program for NET patients.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmaceutical Therapy
Background:
- Neuroendocrine tumors (NETs), particularly Gastroenteropancreatic (GEP) NETs, overexpress somatostatin subtype receptor 2.
- 177Lu-DOTATATE, a novel peptide receptor radiopharmaceutical therapy (PRRT), was approved by the FDA in 2018.
- This therapy targets SSTR-positive NETs, marking a significant advancement in orphan disease treatment.
Purpose of the Study:
- To review the clinical considerations for establishing a 177Lu-DOTATATE treatment program.
- To provide a comprehensive overview of implementing this advanced NET therapy.
Main Methods:
- Review of receptor-based NET radiopharmaceuticals.
- Analysis of 177Lu-DOTATATE patient selection criteria and administration.
- Examination of clinical, regulatory, and radiation safety factors.
- Assessment of technical aspects, tissue dosimetry, and reimbursement.
Main Results:
- 177Lu-DOTATATE has significantly impacted NET patient management.
- The implementation of a PRRT program requires careful consideration of multiple factors.
- Successful program implementation necessitates a multidisciplinary approach.
Conclusions:
- 177Lu-DOTATATE represents a paradigm shift in treating SSTR-positive NETs.
- Effective implementation hinges on addressing patient selection, administration, safety, and logistics.
- This review provides essential guidance for healthcare providers offering this innovative therapy.
More Related Videos
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020